Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling

Fig. 4

Emab selectively inhibits PRDM1 mRNA expression in CD10–CD27– B cells. a Network of transcription factors involved in B-cell differentiation into Ab-producing cells. b–d Tonsillar CD10–CD27– B cells were negatively selected using magnetic bead cell separation and then stimulated with R848 (TLR7 agonist) and/or F(ab′)2 anti-human IgM with or without Emab or a human IgG control. RNA was isolated 12 hours after stimulation and expression of different genes was quantified by RT-PCR. *p < 0.05, **p < 0.01 as determined by two-way ANOVA with Bonferroni post test. Emab epratuzumab

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us